Clinical Trial Update: Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions [Phase 2]

View source ↗

Summary

A completed Phase 2 safety study comparing ICL670 with deferoxamine in sickle cell disease patients with transfusional iron overload.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Deferoxamine (deferoxamine)
• ICL670

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Anemia, Sickle Cell | Phase 2 | Status: COMPLETED